Although no targeted therapies are yet available for these TP53 mutations, in a recent study, tumor infiltrating T‐cell responses to two TP53 hotspot mutations G245S and Y220C were identified in the context of HLA‐DRB3*02:02 in two separate ovarian cancer patients.20 Among the tumors sequenced in this cohort, five harbored the TP53 Y220C mutation and one had the G245S mutation. This evidence concerns the gene TP53 and neoplasm.